The bromodomain and extra-terminal (BET) family proteins, consisting of BRD2, BRD3, BRD4, and testis-specific BRDT members, are epigenetic “readers” and play a key role in the regulation of gene transcription. BET proteins are considered to be attractive therapeutic targets for cancer and other human diseases. Recently, heterobifunctional small-molecule BET degraders have been designed based upon the proteolysis targeting chimera (PROTAC) concept to induce BET protein degradation. Herein, we present our design, synthesis, and evaluation of a new class of PROTAC BET degraders. One of the most promising compounds, 23, effectively degrades BRD4 protein at concentrations as low as 30 pM in the RS4;11 leukemia cell line, achieves an IC50 value of 51 pM in inhibition of RS4;11 cell growth and induces rapid tumor regression in vivo against RS4;11 xenograft tumors. These data establish that compound 23 (BETd-260/ZBC260) is a highly potent and efficacious BET degrader.

Circularly polarized light (CPL) exhibits an enantioselective interaction with chiral molecules, providing a pathway toward all-optical chiral resolution. High index dielectric nanoparticles have been shown to enhance this relationship, but with a spatially varying sign (or enantiospecificity) that yields a near zero spatially averaged enhancement. Using full field electromagnetic simulations, we design metasurfaces consisting of high index dielectric disks that provide large-volume, uniform-sign enhancements in both the optical density of chirality, C (the figure of merit for sensing and spectroscopy), and Kuhn’s dissymmetry factor, g (the figure of merit for separation). By varying disk radius, we achieve local enhancements in C and g up to 138-fold and 15-fold, respectively, as well as volumetric enhancements of 30-fold and 4.2-fold. The uniform-sign enhancements in C occur near the first Kerker condition, where overlapping electric and magnetic modes maximize field strength and preserve the π/2 phase lag between the electric and magnetic fields of CPL; in contrast, uniform-sign enhancements in g occur with spectrally separated modes, where fields and phase remain optimal without reduced molecular absorption. Using first-order kinetics of the molecule thiocamphor, we show how this optically enantiopure metasurface could enable 20% enantiomeric excesses with a >2000-fold increase in yield for a photoionization reaction compared to CPL alone.

Proteins of the bromodomain and extra-terminal (BET) family are epigenetics "readers" and promising therapeutic targets for cancer and other human diseases. We describe herein a structure-guided design of [1,4]oxazepines as a new class of BET inhibitors and our subsequent design, synthesis, and evaluation of proteolysis-targeting chimeric (PROTAC) small-molecule BET degraders. Our efforts have led to the discovery of extremely potent BET degraders, exemplified by QCA570, which effectively induces degradation of BET proteins and inhibits cell growth in human acute leukemia cell lines even at low picomolar concentrations. QCA570 achieves complete and durable tumor regression in leukemia xenograft models in mice at well-tolerated dose-schedules. QCA570 is the most potent and efficacious BET degrader reported to date.

The estrogen receptor (ER) is a validated target for the treatment of estrogen receptor-positive (ER+) breast cancer. Here, we describe the design, synthesis, and extensive structure–activity relationship (SAR) studies of small-molecule ERα degraders based on the proteolysis targeting chimeras (PROTAC) concept. Our efforts have resulted in the discovery of highly potent and effective PROTAC ER degraders, as exemplified by ERD-308 (32). ERD-308 achieves DC50 (concentration causing 50% of protein degradation) values of 0.17 and 0.43 nM in MCF-7 and T47D ER+ breast cancer cell lines, respectively, and induces >95% of ER degradation at concentrations as low as 5 nM in both cell lines. Significantly, ERD-308 induces more complete ER degradation than fulvestrant, the only approved selective ER degrader (SERD), and is more effective in inhibition of cell proliferation than fulvestrant in MCF-7 cells. Further optimization of ERD-308 may lead to a new therapy for advanced ER+ breast cancer.

Triple-negative breast cancers (TNBC) remain clinically challenging with a lack of options for targeted therapy. In this study, we report the development of a second-generation BET bromodomain (BRD) inhibitor, BETd-246, which exhibits superior selectivity, potency and antitumor activity. In human TNBC cells, BETd-246 induced degradation of BET transcription factors at low nanomolar concentrations within 1 hr of exposure, resulting in robust growth inhibition and apoptosis. BETd-246 was more potent and effective in TNBC cells than its parental BET inhibitor compound BETi-211. RNA-seq analysis revealed predominant downregulation of a large number of genes involved in proliferation and apoptosis in cells treated with BETd-246, as compared to BETi-211 treatment which upregulated and downregulated a similar number of genes. Functional investigations identified the MCL1 gene as a critical downstream effector of these BET degraders, which synergized with small molecule inhibitors of BCL-xL in triggering apoptosis. In multiple murine xenograft models of human breast cancer, BETd-246 and a further optimized analogue BETd-260 effectively depleted BET proteins in tumors and exhibited strong antitumor activities at well-tolerated dosing schedules. Overall, our findings show how specific targeting of BET proteins for degradation yields an effective therapeutic strategy for TNBC treatment.

In a previous analysis of 2300 mRNAs via whole-mount fluorescent in situ hybridization in cellularizing Drosophila embryos, we found that 70% of the transcripts exhibited some form of subcellular localization. To see whether this prevalence is unique to early Drosophila embryos, we examined ∼8000 transcripts over the full course of embryogenesis and ∼800 transcripts in late third instar larval tissues. The numbers and varieties of new subcellular localization patterns are both striking and revealing. In the much larger cells of the third instar larva, virtually all transcripts observed showed subcellular localization in at least one tissue. We also examined the prevalence and variety of localization mechanisms for >100 long noncoding RNAs. All of these were also found to be expressed and subcellularly localized. Thus, subcellular RNA localization appears to be the norm rather than the exception for both coding and noncoding RNAs. These results, which have been annotated and made available on a recompiled database, provide a rich and unique resource for functional gene analyses, some examples of which are provided.

Chiral-optical spectroscopies, such as circular dichroism, are critical in the biomedical, pharmaceutical, and agrochemical industries for revealing structural information about molecules and determining the purity of chemical samples. Emerging nanophotonic platforms have been shown to increase the intrinsically weak interaction between circularly polarized light and chiral molecules through the concentration of the local density of optical chirality, C. However, enhancements in C have been limited to infrared and visible frequencies, while the chiral absorption features of most small molecules are in the ultraviolet. Furthermore, achievable C enhancements in nanophotonic systems remain relatively low, especially when averaged across the sample volume. Here, we use full-field simulations to design a high quality factor (high Q) diamond metasurface that enhances C by over 3 orders of magnitude in the ultraviolet regime. The diamond nanostructures enable ultraviolet Mie resonances while a biperiodic disk lattice activates high Q resonances that significantly increase the electromagnetic field intensities. When a high Q electric dipole and magnetic dipole mode are spatially and spectrally overlapped, a Kerker-like condition emerges that enables uniform sign C enhancements that are locally as high as 1130-fold. Even when averaged across the unit cell and 40 nm away from the surface, enhancements in C exceed 100-fold. We show how the quality factor and C can be further tuned by adjusting the structural asymmetry via the diameter offset in the biperiodic lattice. Our results pave the way for ultrasensitive chiral spectroscopy and efficient light-mediated enantiomer separation.

Strong enhancement of molecular circular dichroism (CD) has the potential to enable efficient asymmetric photolysis, a method of chiral separation that has conventionally been impeded by insufficient yield and low enantiomeric excess.Here, we study experimentally how predicted enhancements in optical chirality density near resonant silicon nanodisks boost CD. We use fluorescence-detected circular dichroism (FDCD) spectroscopy to measure indirectly the differential absorption of circularly polarized light by a monolayer of optically active molecules functionalized to silicon nanodisk arrays. Importantly, the molecules and nanodisk antennas have spectrally coincident resonances, and our fluorescence technique allows us to deconvolute absorption in the nanodisks from the molecules. We find that enhanced FDCD signals depend on nanophotonic resonances, in good agreement with simulated differential absorption and optical chirality density, while no signal is detected from molecules adsorbed on featureless silicon surfaces. These results verify the potential of nanophotonic platforms to be used for asymmetric photolysis with lower energy requirements.